ESR1 and breast cancer: TN-BC is defined by immunohistochemistry as lacking the estrogen receptor (ER-negative), the progesterone receptor that is normally induced by functional estrogen receptor (PR-negative) and lacking the human epidermal growth factor 2 (Her2) receptor overexpression or amplification as well (Her2-negative).